Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce E Strober

Showing results (41-50 of 86) with videos related to

Pageof 9
Sort By:
The Journal of Dermatological Treatment|May 1, 2019
US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis RegistryBruce E Strober, Rebecca Germino, Adriana Guana, et al.
Archives of Dermatology|May 17, 2006
Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group studyJames Leyden, Diane M Thiboutot, Alan R Shalita, et al.
Journal of the American Academy of Dermatology|June 2, 2005
Etanercept does not effectively treat moderate to severe alopecia areata: an open-label studyBruce E Strober, Kimberly Siu, Andrew F Alexis, et al.
Dermatology and Therapy|May 11, 2025
Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient OutcomesBruce E Strober, Michael Bukhalo, April W Armstrong, et al.
Expert Opinion on Biological Therapy|March 27, 2013
Pharmacovigilance and biosimilars: considerations, needs and challengesNicole Casadevall, I Ralph Edwards, Thomas Felix, et al.
The Journal of Dermatological Treatment|March 8, 2017
Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumabBoni E Elewski, Lluís Puig, Margaret Mordin, et al.
Journal of Drugs in Dermatology : JDD|March 4, 2026
Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World EvidenceMark G Lebwohl, James G Krueger, John Y Koo, et al.
Drug Safety|February 11, 2019
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development ProgramsSubrata Ghosh, Lianne S Gensler, Zijiang Yang, et al.
Journal of the American Academy of Dermatology|June 20, 2006
A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitisDonald Belsito, David C Wilson, Erin Warshaw, et al.
The Journal of Dermatological Treatment|February 7, 2020
Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis RegistryAbby S Van Voorhees, Marc A Mason, Leslie R Harrold, et al.
Pageof 9

Showing results (41-50 of 86) with videos related to

Sort By:
Pageof 9
The Journal of Dermatological Treatment|May 1, 2019
US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis RegistryBruce E Strober, Rebecca Germino, Adriana Guana, et al.
Archives of Dermatology|May 17, 2006
Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group studyJames Leyden, Diane M Thiboutot, Alan R Shalita, et al.
Journal of the American Academy of Dermatology|June 2, 2005
Etanercept does not effectively treat moderate to severe alopecia areata: an open-label studyBruce E Strober, Kimberly Siu, Andrew F Alexis, et al.
Dermatology and Therapy|May 11, 2025
Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient OutcomesBruce E Strober, Michael Bukhalo, April W Armstrong, et al.
Expert Opinion on Biological Therapy|March 27, 2013
Pharmacovigilance and biosimilars: considerations, needs and challengesNicole Casadevall, I Ralph Edwards, Thomas Felix, et al.
The Journal of Dermatological Treatment|March 8, 2017
Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumabBoni E Elewski, Lluís Puig, Margaret Mordin, et al.
Journal of Drugs in Dermatology : JDD|March 4, 2026
Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World EvidenceMark G Lebwohl, James G Krueger, John Y Koo, et al.
Drug Safety|February 11, 2019
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development ProgramsSubrata Ghosh, Lianne S Gensler, Zijiang Yang, et al.
Journal of the American Academy of Dermatology|June 20, 2006
A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitisDonald Belsito, David C Wilson, Erin Warshaw, et al.
The Journal of Dermatological Treatment|February 7, 2020
Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis RegistryAbby S Van Voorhees, Marc A Mason, Leslie R Harrold, et al.
Pageof 9